Analysis-SpaceX debut draws a crowd, but few recent hot IPOs outpace the market

Reuters’ analysis of the 50 highest-valued IPOs over the past five years found investors would have been better off buying an S&P 500 index fund about three-quarters of the time. The average IPO investor was up 27% versus 53% for the S&P 500 over comparable periods, highlighting the risk of paying rich valuations before debut. The piece warns that SpaceX’s expected $1.75 trillion valuation and nearly 100x price-to-sales ratio could leave little upside despite strong AI/tech demand.

Analysis

The key market takeaway is not that expensive IPOs underperform broadly; it is that the underperformance is concentrated in listings where valuation is decoupled from near-term cash generation. That matters for the current AI/venture pipeline because the marginal buyer is being asked to underwrite far more execution risk than the public-market comps imply, while liquidity arrives only after the strongest private-side returns have already been captured. In that setup, the first trade tends to be a valuation air-pocket, not a fundamentals rerating.

Second-order winners are the listed infrastructure and picks-and-shovels names with real revenue visibility and lower duration risk. ALAB stands out as the cleaner beneficiary versus future headline IPOs because it sells into the AI capex stack without depending on a perfect product narrative; NVDA remains the benchmark, but its valuation is still anchored by current monetization rather than a distant TAM story. By contrast, RIVN and FIG remain the cautionary templates: both showed how high-profile debuts can create a temporary scarcity premium that later mean-reverts once the market shifts from story to unit economics.

The contrarian point is that the market may be underestimating how much capital formation will be absorbed by these debuts at the expense of secondary AI winners. When a mega-IPO hits, it can pull incremental risk capital out of the same cohort of growth funds and retail flows that has supported mid-cap AI/tech momentum, creating short-lived relative weakness in the rest of the basket. That makes the next 1-3 months more about flow and positioning than about long-term TAM, and the setup favors fading crowded enthusiasm rather than chasing the first print.

On the fundamental side, the biggest hidden risk is that a rich IPO window can tighten the discount rates applied to private-market assets if the debut disappoints. If the first post-listing weeks see a drawdown, secondary sales in adjacent venture names may accelerate and force markdowns across the AI/private-markets complex, which would be a negative catalyst for sentiment over the next quarter.

Key Decisions for Investors

• Fade the expected IPO hype with a short-duration put spread on the debut name or its closest listed proxy once pricing is finalized; look for 30-90 day expiry to capture post-listing valuation compression without paying for long-dated optionality.
• Long ALAB vs. short RIVN as a quality-growth pair trade over the next 1-3 months; ALAB benefits from AI capex persistence while RIVN remains exposed to cash burn and credibility discount, offering cleaner relative downside if growth factors de-rate.
• Keep a tactical long in NVDA as the lower-duration AI beneficiary versus private-market peers; use dips around IPO-driven factor rotation to add, with a 3-6 month horizon and a tighter stop if AI capex data rolls over.
• Avoid initiating fresh long exposure in FIG-like narrative IPOs for the first 4-6 weeks after debut unless valuation resets at least 20-30% below the issue price; post-IPO supply is usually the better entry than the opening tape.
• For liquid hedge book management, consider a temporary short basket of high-beta software/venture proxies against a long basket of profitable AI infrastructure names to isolate the flow-driven unwind risk from the broader tech factor.